ArticleYonsei medical journal2026
Continuous Glucose Monitoring-Driven Personalization of Cornstarch Therapy in Glycogen Storage Disease: A Retrospective Analysis.
Article in Yonsei medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genotype-phenotype spectrum and clinical outcomes of glycogen storage disease type I: A 15-year experience at Vietnam National Children's Hospital.Molecular genetics and metabolism reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeHepatic glycogen storage diseases (GSD), including types Ia, Ib, and IXa, are rare inherited disorders characterized by impaired hepatic glucose homeostasis. In GSD Ia, deficiency of glucose-6-phosphatase results in recurrent hypoglycemia and metabolic disturbances. Uncooked cornstarch (UCCS) is the standard therapy due to its slow digestion and sustained glucose release; however, dosing requirements vary according to age, digestion rate, metabolic demand, and lifestyle. Despite the central role of UCCS in long-term management, real-world data describing extended continuous glucose monitoring (CGM) patterns in hepatic GSD are extremely limited, and objective evidence guiding individualized dose adjustment remains scarce. This study examined CGM profiles in patients with hepatic GSD receiving long-term UCCS therapy and assessed the clinical utility of CGM in guiding individualized dosing adjustments. MATERIALS AND
methodsWe performed a retrospective, multi-year analysis of CGM data from 32 patients with hepatic GSD treated with UCCS. CGM traces were processed using 15-minute resampling, constrained interpolation, and physiologic clipping (40-400 mg/dL). Data were segmented into non-overlapping, calendar-anchored 7- and 14-day windows (anchor at 00:00) and retained when coverage was ≥70%. Per window, we calculated time in range (TIR, 70-150 mg/dL), time below range (TBR, <70 mg/dL), time above range (≥150 mg/dL), coefficient of variation, nocturnal TBR (00:00-06:00), and hypoglycemia burden [area under the curve (AUC) <70 mg/dL].
resultsDuring routine clinic follow-up, CGM-informed, patient-specific UCCS and dietary adjustments maintained high TIR and low glycemic variability. Growth parameters and liver enzyme levels remained within normal limits. Episodes of recurrent nocturnal hypoglycemia identified on CGM prompted targeted modifications of UCCS dosing.
conclusionA CGM-guided approach facilitates personalized UCCS management in hepatic GSD. Systematic review of TIR, nocturnal TBR, and AUC <70 mg/dL, alongside growth and liver assessments, provides a practical framework for optimizing long-term metabolic stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.